Upgrade to SI Premium - Free Trial

Stifel Reiterates Bullish View on Kite Pharma (KITE) Following New Trial News

October 6, 2016 10:12 AM
Stifel analyst Thomas Shrader reiterated a Buy rating and $74 price target on Kite Pharma (NASDAQ: KITE) after the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles